You are here: Industry Insights > NeuroRx

News List

NeuroRx, Relief Announce Fast Track Designation for Respiratory Distress Treatment in COVID-19 americanpharmaceuticalreview
July 03, 2020
NeuroRx, in partnership with Relief Therapeutics, announced the U.S. Food and Drug Administration (FDA) awarded Fast Track Designation to NeuroRx for the investigation of RLF-100 (Aviptadil) for the treatment of acute lung injury ...
FDA grants fast track status to NeuroRx’s Covid-19 drug candidate pharmaceutical-technology
June 28, 2020
The US Food and Drug Administration (FDA) has granted fast track designation to RLF-100 (Aviptadil), which is being developed by NeuroRx and Relief Therapeutics to treat acute lung injury / acute respiratory distress syndrome caused by Covid-19.
Relief Therapeutics, NeuroRx Expand Clinical Trial of RLF-100 americanpharmaceuticalreview
June 16, 2020
Relief Therapeutics and its U.S. partner, NeuroRx, announced the Phase 2/3 clinical trial evaluating RLF-100 as a treatment for critical COVID-19 with respiratory failure has been expanded to include patients receiving high flow oxygen and ...
Relief Therapeutics, NeuroRx Begin RLF-100 Study for COVID-19 Associated ARDS americanpharmaceuticalreview
June 10, 2020
Relief Therapeutics and its U.S. partner, NeuroRx, announced treatment of the first patients with RLF-100 at the University of Miami Miller School of Medicine, FL.
Relief Therapeutics, NeuroRx File IND for Aviptadil for COVID-19-Induced Respiratory Distress americanpharmaceuticalreview
April 01, 2020
Relief Therapeutics and NeuroRx have filed an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) ...
NeuroRx Initiates Study for Breakthrough Therapy Targeting Suicidal Bipolar Depression drugs
July 12, 2019
Will test oral antidepressant, NRX-101, in maintaining remission from Severe Bipolar Depression.
NeuroRx Initiates NRX-101 Study for Suicidal Bipolar Depression americanpharmaceuticalreview
July 11, 2019
NeuroRx has initiated a pivotal Phase 2b/3 study for NRX-101 for the treatment of patients with Severe Bipolar Depression and Acute Suicidal Ideation and Behavior (ASIB).
NeuroRx Reports Phase 2 Efficacy for NRX-101 americanpharmaceuticalreview
May 31, 2019
NeuroRx announced statistically significant final results from its Phase 2 STABIL-B study of NRX-101 versus lurasidone in patients with Severe Bipolar Depression and Acute Suicidal Ideation or Behavior (ASIB).
NeuroRx plans pivotal trial after seeing hints of efficacy in suicidal patients fiercebiotech
December 26, 2018
NeuroRx is planning to move NRX-101 into phase 2b/3 after detecting signs of efficacy in a feasibility trial in patients with suicidal bipolar depression.
NeuroRx Awarded Fast Track Designation for Regimen Targeting Suicide in Bipolar Depression americanpharmaceuticacreview
September 07, 2017
NeuroRx has been granted Fast Track status by the U.S. Food and Drug Administration (FDA) for its sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone).

Previous page 1 2 Next page